Plaintiff

Opiant Pharmaceuticals, Inc.

3 cases as plaintiff.

Cases
3
Active
0
3 closed
Filed
2016–2018
Top venue
D. New Jersey
3 cases
Also appears as a defendant in 4 cases → View as defendant

Watchlist

Get alerted when Opiant Pharmaceuticals, Inc. sues again.

Email-only, free, anonymous. We'll notify you when Opiant Pharmaceuticals, Inc. files another patent-infringement lawsuit. One-click unsubscribe from any alert.

Adapt Pharma Operations Limited et al. v. Teva Pharmaceuticals USA, Inc. et al.

stayed
Docket:
2:18-cv-05752
Filed:
2018-04-09
Terminated:
2022-07-27
Patents:94806449707226
π Adapt Pharma Operations Limitedπ Adapt Pharma Inc.π Adapt Pharma Limitedπ Opiant Pharmaceuticals, Inc.Δ Teva Pharmaceuticals USA, Inc.Δ Teva Pharmaceuticals Industries Ltd.

Hatch-Waxman/ANDA suit filed by Adapt Pharma and Opiant against Teva, triggered by Teva's Paragraph IV notice regarding ANDA No. 211561 for generic NARCAN 2 mg/spray. The case asserted U.S. 9,480,644 and U.S. 9,707,226. On July 28, 2020, the court stayed the case pending resolution of the related 4 mg Naloxone Case appeal; the final docket entry is dated July 27, 2022.

Adapt Pharma Operations Limited et al. v. Teva Pharmaceuticals USA, Inc. et al.

judgment (invalidity); affirmed on appeal
Docket:
2:16-cv-07721 (JLL)(JAD); 2:17-cv-00864; 2:17-cv-02877; 2:17-cv-05100; 2:18-cv-09880
Filed:
2016-11-26
Terminated:
2020-06-26
Patents:9192570946874795611779629965977583810085937
π Adapt Pharma Operations Limitedπ Adapt Pharma Inc.π Adapt Pharma Limitedπ Opiant Pharmaceuticals, Inc.Δ Teva Pharmaceuticals USA, Inc.Δ Teva Pharmaceuticals Industries, Ltd.

Adapt and Opiant sued Teva in D.N.J. asserting NARCAN naloxone nasal spray patents. The district court found the asserted patents invalid for obviousness on June 5, 2020, with judgment entered June 26, 2020; the Federal Circuit affirmed on Feb. 10, 2022. The '570 patent was not asserted but was cited as prior art (Wyse). Consolidated/related docket numbers included 2:17-cv-00864, 2:17-cv-02877, 2:17-cv-05100, 2:18-cv-09880; related Perrigo action 2:18-cv-15287.

Adapt Pharma Operations Limited et al. v. Perrigo UK FINCO Limited Partnership

related action
Docket:
2:18-cv-15287
Patents:9192570946874795611779629965977583810085937
π Adapt Pharma Operations Limitedπ Adapt Pharma Inc.π Adapt Pharma Limitedπ Opiant Pharmaceuticals, Inc.Δ Perrigo UK FINCO Limited Partnership

Related Perrigo action in the D.N.J. NARCAN litigation; Perrigo UK FINCO Limited Partnership named as defendant. The '570 patent was not asserted; it was prior art (Wyse) in the related litigation.